Last reviewed · How we verify

NCT04357184: BFRT

BFRT for Severe Lower Extremity Muscle Atrophy

Completed NA Last updated 16 February 2022
What this trial tests

NA trial testing Blood flow restriction training in Severe Muscle Atrophy in 100 participants. Completed in 15 February 2022.

Timeline
14 April 2020
Primary endpoint
15 February 2022
15 February 2022

Quick facts

Lead sponsorCincinnati Sportsmedicine Research and Education Foundation
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment100
Start date14 April 2020
Primary completion15 February 2022
Estimated completion15 February 2022
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Cincinnati Sportsmedicine Research and Education Foundation

Who can join

Eligibility, any sex, with Severe Muscle Atrophy or Muscle Weakness. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Muscle weakness or atrophy is a common condition following acute and chronic musculoskeletal injuries. Strength training is an imperative component in clinical rehabilitation of musculoskeletal injuries. Heavy exercise loads (approximately 70% of one repetition maximum) is necessary to elicit muscle hypertrophy and strength gains. However, patients with severe muscle atrophy are frequently unable to tolerate these loads due to pain. Blood flow resistance training with low resistance loads may be used to safely develop muscle strength.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Blood flow restriction training

Trials testing the same drug.

Other Cincinnati Sportsmedicine Research and Education Foundation trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04357184.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing